The broad goal of this study was to examine the efficacy and tolerability of vortioxetine
(flexible dose) for the treatment of major depressive disorder (MDD) in symptomatic women
around the menopausal transition. We hypothesized that an eight-week treatment with
vortioxetine would promote a significant improvement of depression symptoms and other
menopause-related physical symptoms.